Skip to Content
Morningstar

Voyager Therapeutics Inc VYGR

Morningstar Rating
Unlock
Stock XNAS Rating as of
$7.74 −0.24 (3.01%)
View Full Chart
As of Delayed Price Pre-Open: $7.70 0.00
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
VYGR is trading within a range we consider fairly valued.
Price
$7.78
Fair Value
$63.37
Uncertainty
Extreme
1-Star Price
$31.49
5-Star Price
$7.57
Economic Moat
Psys
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VYGR is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$7.98
Day Range
$7.70–8.04
52-Week Range
$6.06–14.34
Bid/Ask
$7.58 / $8.53
Market Cap
$420.29 Mil
Volume/Avg
56 / 680,070

Key Statistics

Price/Earnings (Normalized)
2.58
Price/Sales
1.42
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
162
Website
https://www.voyagertherapeutics.com

Comparables

Valuation

View More
Metric
VYGR
CELC
TGTX
Price/Earnings (Normalized)
 2.58—17.67
Price/Book Value
 1.493.1013.21
Price/Sales
 1.42—8.90
Price/Cash Flow
 2.46—39.05
Price/Earnings
VYGR
CELC
TGTX

Financial Strength

Metric
VYGR
CELC
TGTX
Quick Ratio
 4.8912.785.00
Current Ratio
 4.9613.435.92
Interest Coverage
 —−12.432.04
Quick Ratio
VYGR
CELC
TGTX

Profitability

Metric
VYGR
CELC
TGTX
Return on Assets (Normalized)
 49.26%−35.57%19.44%
Return on Equity (Normalized)
 80.87%−49.08%54.76%
Return on Invested Capital (Normalized)
 66.23%−39.21%35.76%
Return on Assets
VYGR
CELC
TGTX
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRYshyyfyfmhCbw$553.3 Bil
VRTX
Vertex Pharmaceuticals IncSkhbntjsRcncp$101.6 Bil
REGN
Regeneron Pharmaceuticals IncRclcwqtsYgswn$98.9 Bil
MRNA
Moderna IncQvhhtttTfrj$39.7 Bil
ARGX
argenx SE ADRZsndhzvrVwnf$21.5 Bil
BNTX
BioNTech SE ADRMdcqlcjTdpt$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncBkhgmgdKrmdw$18.4 Bil
BMRN
Biomarin Pharmaceutical IncZnjkystlKpsnknk$17.2 Bil
RPRX
Royalty Pharma PLC Class AXfjddtnhlFhhxh$12.3 Bil
INCY
Incyte CorpGyfwhwrrdXjtnpvz$11.8 Bil

Sponsor Center